CA-LASERFICHE
16.4.2024 15:01:33 CEST | Business Wire | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has announced a number of channel momentum milestones as the organization marks the start of a new era of growth and technology innovation. In 2024, the company is strengthening its partner ecosystem to deliver more ways for organizations to transform the way they manage content, automate workflows and accelerate how business gets done.
“We’ve seen incredible progress across all areas of Laserfiche over the past year, including growth into emerging industries and regions, increased investment into our channel program and resources, and hiring of key leaders,” said Laserfiche CEO Karl Chan. “In 2024, we look forward to building on this momentum, continuing to strengthen our partner ecosystem and bringing even more solutions to market that empower organizations and inspire the world.”
Expanding Global Footprint
Over the past year, Laserfiche saw widespread adoption of digital transformation initiatives in all global regions, with particular growth in EMEA. Testament to this, MBS, a nearly 20-year-old Laserfiche Solution Provider that has customers in 49 countries worldwide, experienced 200% growth in the number of Laserfiche users served. For its success, MBS earned the 2024 Laserfiche International Partner of the Year Award.
“In recent years, we have seen a marked increase in the demand for digital transformation, and Laserfiche is the ideal solution,” said MBS Managing Director Rupert Leaton. “We’re proud to partner with a world-leading vendor for intelligent content management and business process automation, which stays ahead of the curve when it comes to providing innovative solutions for our customers.”
Bolstering Channel Success
In 2024, Laserfiche is building on the momentum with enhancements to its award-winning Solution Provider Program, including new product trainings, sales and marketing resources to support partners. The newly introduced Premier Partner Program increases visibility of highly qualified solution providers and helps to connect them to customers that can best leverage their business and solutions expertise.
Additional new benefits to the Laserfiche Solution Provider Program include a reimagined Winners Circle event to celebrate the top sales achievers annually; open forums for the Laserfiche sales community to share knowledge and strategy; a solution provider track at the annual Laserfiche Empower Conference; and the opportunity to participate in regular advisory councils to influence sales campaigns and resources, product roadmap and more.
Award-Winning Partner Program
“With the growing demand for information management and process automation solutions that also provide enterprise-level information governance, integration and scalability tools, Laserfiche channel partners are uniquely positioned for success,” said Vicki VanValin, vice president of sales at Laserfiche. “We are committed to leading the industry by providing our partners with innovative technology, robust resources and best-in-class service.”
In 2024, The Laserfiche Solution Provider Program earned a 5-star rating in the 2024 Partner Program Guide by CRN, a brand of The Channel Company. The rating is awarded to the companies that go above and beyond in their commitment to nurturing strong, profitable, successful channel partnerships.
Laserfiche’s employees are continually recognized across the channel for their participation and achievements. In February, three of its channel leaders were named to CRN’s 2024 Channel Chief list, including Taylor Grosso, senior director of Global Channels and Alliances, Charles Suzara, associate director – west, and Vicki VanValin, vice president of sales. The prestigious CRN Channel Chiefs list, released annually, recognizes IT vendor and distribution executives who are driving strategy and setting the channel agenda for their companies. In 2023, three others were named to CRN’s Women of the Channel list, including Jann Michishima, partner marketing manager; Nicole Moulton, senior technical trainer; and Kathleen Park, presales manager.
“From getting channel partners the resources they need to ongoing communication and collaboration, Laserfiche’s channel support is among the strongest in the industry,” said Grosso. “Our award-winning channel leadership is dedicated to enabling our partners to achieve their goals, and provide exceptional value to customer organizations around the world.”
Laserfiche will unveil additional enhancements and investments in its channel program in the coming months. To learn more about the Laserfiche Solution Provider Program and the benefits of becoming a partner, visit laserfiche.com/partners.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter/X | LinkedIn | Facebook
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416107538/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
